PHAT Phathom Pharmaceuticals

Phathom Pharmaceuticals to Present at Upcoming Investor Conferences

Phathom Pharmaceuticals to Present at Upcoming Investor Conferences

FLORHAM PARK, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, President and Chief Executive Officer and Azmi Nabulsi, M.D., Chief Operating Officer, will present at three upcoming virtual investor conferences in June, including:

  • Jefferies Virtual Healthcare Conference

    Date: June 3, 2020

    Time: 3:30 pm EDT



  • Goldman Sachs 41st Annual Global Healthcare Conference 

    Date: June 11, 2020

    Time: 2:10 pm EDT

  • BMO Prescriptions for Success Healthcare Conference

    Date: June 23, 2020

    Time: 4:00 pm EDT

Executive management will also participate in one-on-one meetings during the conferences.

To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at .  Recordings will be available for 30 days following each event.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company’s website at or follow the Company on LinkedIn at .

CONTACTS

Media Contacts:

Joe Hand

1-877-742-8466

Nick Benedetto

1-877-742-8466

Investor Contact:

Patti Bank

Westwicke Partners

415-513-1284

EN
28/05/2020

Underlying

PHATPhathom Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Phathom Pharmaceuticals

 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results ...

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to $175 millionCompany remains focused on path to profitability in 2026Management to host conference call today, August 7, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and ...

August 7, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Result...

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, August 7, 2025, to report its second quarter 2025 financial results and provide a business u...

July 28, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listi...

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company’s Board of Directors has approved the grant of inducement awards. On June 23, 2025, the Compensation Committee of the Company’s Board of Directors...

June 23, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Office...

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance...

June 23, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listin...

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032 FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has updated the Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”) to accurately reflect the full 10...

June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch